KRIYA‑497 / Kriya Therap - LARVOL DELTA

Kriya Acquires Tramontane Therapeutics and Launches Gene Therapy Program for Nonalcoholic Steatohepatitis (NASH) and Other Prevalent Diseases (GlobeNewswire) - "Kriya anticipates advancing its NASH gene therapy candidate into the clinic by 1H 2025...Kriya's gene therapy candidate for treating people with NASH may have the following benefits: One-time intramuscular AAV administration may eliminate compliance issues associated with complex medication regimens; Continuous expression of FGF21 delivers a steady level of the protein, to avoid peak-to-trough pharmacokinetic variability associated with repeatedly-injected recombinant analog products, which may lead to better treatment outcomes"

Clinical • New trial • Metabolic Dysfunction-Associated Steatohepatitis

Kriya Acquires Tramontane Therapeutics and Launches Gene Therapy Program for Nonalcoholic Steatohepatitis (NASH) and Other Prevalent Diseases (GlobeNewswire) - "Kriya Therapeutics, Inc...announced that it has acquired Tramontane Therapeutics, Inc. ('Tramontane'). Tramontane is a private gene therapy company focused on developing treatments for metabolic and neurodegenerative diseases. Tramontane, a spin out from Universitat Autònoma de Barcelona (UAB), is now a wholly owned subsidiary of Kriya. With the transaction, Kriya acquires a portfolio of Fibroblast Growth Factor 21 (FGF21) assets including Tramontane’s lead program, an adeno-associated virus (AAV) vector designed to express a steady level of the native FGF21 protein. FGF21 has beneficial metabolic effects across several target organs including the liver."

M&A • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis